The flu vaccine is its first using mRNA technology for influenza.

The Food and Drug Administration rejected Moderna's new flu shot. This raises questions about what it means for the future of vaccine development.

Moderna noted the FDA did not identify any specific safety concerns with the vaccine and that the rejection was inconsistent with previous feedback.

The Food and Drug Administration on Wednesday defended its rejection of Moderna’s mRNA-based flu vaccine application, saying the company’s clinical trial design put patients at risk ...

America’s drug safety agency declined to review a next-gen flu vaccine that uses the same tech as the coronavirus shots ...

After the FDA’s decision to reject a review of Moderna’s mRNA-1010 flu shot, executives explain what Americans will miss out on as other nations embrace the technology.

By Mariam Sunny and Michael Erman Feb 13 (Reuters) - Moderna said it is looking for growth overseas after the U.S. FDA ...

The head of the agency’s vaccine division, Vinay Prasad, has overruled pushback from career staffers.

Centivax has commenced participant dosing in its Phase Ia clinical trial, assessing Centi-Flu 01, a pan-influenza universal ...

The Food and Drug Administration rejected Moderna’s application for its mRNA-based flu vaccine, the drugmaker said Tuesday ...

The US pharma firm’s 40,000-person study suggested its new shot was more effective than a standard flu vaccine.

Correction: This story was updated to clarify a statement given by Department of Health and Human Services spokesperson Andrew Nixon. Moderna said on Tuesday that the Food and Drug Administration (FDA ...